Published 18 days ago • loading... • Updated 18 days ago

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

Sales of Sandoz GmbH in Kundl fell slightly in the previous year to 1.63 billion euros, this year is expected to increase. In view of the price pressure on antibiotics, pharmaceutical companies once again appeal to politics.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

Tiroler Tageszeitung Online

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

18 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources1

Leaning Left0Leaning Right0Center0Last Updated18 days agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Tiroler Tageszeitung Online broke the news 18 days ago on Friday, October 16, 2026.

Sources are mostly out of (0)

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

1 Articles

1 Articles

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

Coverage Details

Bias Distribution

Factuality

Ownership

More stories like this

Americans Vote in Midterms as Trump Faces Congressional Test

Washington Post: Elon Musk Explores SpaceX Deal to Enter U.S. Wireless Phone Market

Former AJHL, BCHL broadcaster, front office exec charged with sex crimes against minors

Google AI chatbot's use of press items may infringe copyright rules, EU court adviser says

Attackers ambush police in Nigeria's Zamfara, killing at least eight, officials say

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Similar News Topics

Similar News Topics

More stories like this

Americans Vote in Midterms as Trump Faces Congressional Test

Washington Post: Elon Musk Explores SpaceX Deal to Enter U.S. Wireless Phone Market

Former AJHL, BCHL broadcaster, front office exec charged with sex crimes against minors

Google AI chatbot's use of press items may infringe copyright rules, EU court adviser says

Attackers ambush police in Nigeria's Zamfara, killing at least eight, officials say

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

1 Articles

1 Articles

Translate IconSandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

Coverage Details

Bias Distribution Too Big Arrow Icon

Factuality Info Icon

Ownership

More stories like this

Americans Vote in Midterms as Trump Faces Congressional Test

Washington Post: Elon Musk Explores SpaceX Deal to Enter U.S. Wireless Phone Market

Former AJHL, BCHL broadcaster, front office exec charged with sex crimes against minors

Google AI chatbot's use of press items may infringe copyright rules, EU court adviser says

Attackers ambush police in Nigeria's Zamfara, killing at least eight, officials say

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Similar News Topics

Similar News Topics

More stories like this

Americans Vote in Midterms as Trump Faces Congressional Test

Washington Post: Elon Musk Explores SpaceX Deal to Enter U.S. Wireless Phone Market

Former AJHL, BCHL broadcaster, front office exec charged with sex crimes against minors

Google AI chatbot's use of press items may infringe copyright rules, EU court adviser says

Attackers ambush police in Nigeria's Zamfara, killing at least eight, officials say

Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.

Sandoz Kundl Appeals to the Policy: "Price Drop in Antibiotics as a Risk"

Bias Distribution

Factuality